Why it matters
If confirmed and adopted in practice, the findings could matter to patients and clinicians considering treatment for this cancer. The supplied report is too limited to establish how the results might change care.
RESEARCH & TREATMENTS • UNITED STATES
Report says durvalumab combination improved survival in bladder cancer study
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
MedPage Today reports that perioperative durvalumab plus enfortumab vedotin improved event-free and overall survival compared with radical cystectomy in patients with muscle-invasive bladder cancer. The report provides no study size, trial phase, publication status, or regulatory status.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections